Macrogenics (MGNX) Capital Expenditures (2012 - 2026)
Macrogenics (MGNX) posted quarterly Capital Expenditures of $276000.0 for Q1 2026, down 21.81% year-over-year from $353000.0 in Q1 2025, and up 487.23% quarter-over-quarter from $47000.0 in Q4 2025.
Macrogenics (MGNX) Capital Expenditures (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Capital Expenditures for 15 consecutive years, with $276000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 21.81% year-over-year to $276000.0; the TTM figure through Mar 2026 stood at -$23000.0 (down 100.6% YoY), while the FY2025 annual figure was $54000.0, down 98.54% from the prior year.
- Capital Expenditures advanced to $276000.0 in Q1 2026 per MGNX's latest filing, from $47000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $3.0 million in Q3 2024 and bottomed at -$639000.0 in Q4 2023.
- Historically, Capital Expenditures has averaged $480235.3 across 5 years, with a median of $353000.0 in 2025.
- Annual changes were most pronounced in 2023 — Capital Expenditures sank 262.6% — and 2024, when it surged 511.22%.
- Macrogenics' Capital Expenditures stood at $393000.0 in 2022, then tumbled by 262.6% to -$639000.0 in 2023, then surged by 197.03% to $620000.0 in 2024, then tumbled by 92.42% to $47000.0 in 2025, then soared by 487.23% to $276000.0 in 2026.
- Business Quant data shows MGNX's Capital Expenditures at $276000.0 in Q1 2026, $47000.0 in Q4 2025, and -$26000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 276,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 276,000.00 |
| Mar 31, 2026 | 276,000.00 |
| Dec 31, 2025 | 47,000.00 |
| Dec 31, 2025 | 47,000.00 |
| Sep 30, 2025 | -26,000.00 |
| Sep 30, 2025 | -26,000.00 |
| Jun 30, 2025 | -320,000.00 |
| Jun 30, 2025 | -320,000.00 |
| Mar 31, 2025 | 353,000.00 |
| Mar 31, 2025 | 353,000.00 |
| Dec 31, 2024 | 620,000.00 |
| Dec 31, 2024 | 620,000.00 |
| Sep 30, 2024 | 3.05 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Jun 30, 2024 | -206,000.00 |
| Jun 30, 2024 | -206,000.00 |
| Mar 31, 2024 | 242,000.00 |
| Mar 31, 2024 | 242,000.00 |
| Dec 31, 2023 | -639,000.00 |
| Dec 31, 2023 | -639,000.00 |